PLEASANTON, CA--(Marketwire - June 09, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) announced that the results of a proof-of-concept study that demonstrated a positive therapeutic effect with the Company’s proprietary autologous virus vaccine in SIV-infected non-human primates was published in an original research article entitled, “Delipidated Retroviruses as Potential Autologous Therapeutic Vaccines -- A Pilot Experiment.” The article appeared in Experimental Biology and Medicine (233:732-740,2008). The abstract and article are available on the Company’s website: www.lipidsciences.com under the heading Scientific Abstracts and Publications.
